AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32282044
Drug: Telehealth intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telehealth intervention (ENABLE CHF-PC) consisting of four weekly psychosocial and problem-solving support telephonic sessions lasting 20-60 minutes facilitated by a trained nurse coach plus monthly follow-up for 48 weeks.
Trial: 34979571
Drug: Monthly video
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly video consultations plus regular care (IG)
Trial: 34747448
Drug: Ansofaxine 40
RxNorm normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansofaxine 40 mg/d
Trial: 34747448
Drug: Ansofaxine 80
RxNorm normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansofaxine 80 mg/d
Trial: 34747448
Drug: Ansofaxine 120
RxNorm normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansofaxine 120 mg/d
Trial: 34747448
Drug: Ansofaxine 160
RxNorm normalized name: Ansofaxine
DrugBank: Ansofaxine (DB15052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansofaxine 160 mg/d
Trial: 35372992
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV iron administered proactively
Trial: 35372992
Drug: Low-dose IV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IV iron administered reactively
Trial: 32021087
Drug: 3 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ng/kg/min AM via continuous 12-h intravenous infusion
Trial: 32021087
Drug: 9 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 ng/kg/min AM via continuous 12-h intravenous infusion
Trial: 32021087
Drug: 15 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ng/kg/min AM via continuous 12-h intravenous infusion
Trial: 34617277
Drug: Ketoprofen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (3 mg/kg, Ketofen 10%, Ceva Animal Health)
Trial: 34617277
Drug: Control (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (topical application of oxytetracycline spray only)
Trial: 33724373
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (tenofovir disoproxil fumarate/emtricitabine with a third agent)
Trial: 38609322
Drug: tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 5 mg two times per day
Trial: 38609322
Drug: tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 10 mg two times per day
Trial: 33249580
Drug: Galcanezumab (GMB)
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Galcanezumab (GMB) 120 mg
Trial: 35508860
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) intervention at bilateral Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25), and Zhongwan (RN 12) acupoints, 30 min per time, twice daily, for 7 days
Trial: 33455137
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment group (monosialotetrahexose ganglioside sodium + conventional rehabilitation)
Trial: 33455137
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (conventional rehabilitation)
Trial: 33020204
Drug: Cetuximab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (initial dose of 400 mg/m2 IV followed by weekly doses of 250 mg/m2, one cycle = 4 weeks)
Trial: 34571095
Drug: Lesogaberan (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan (120 mg MR)
Trial: 33287865
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment (MBT) for 12 months
Trial: 33789243
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 5 mg·kg‐1 body mass
Trial: 32781992
Drug: Oral ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ranitidine (3 mg/kg/day) for 10 days
Trial: 32781992
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mg of oral vitamin C tablet) for 10 days
Trial: 35859277
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP ≤ 130 mmHg)
Trial: 35859277
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP ≤ 140 mmHg)
Trial: 34646359
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (n = 33)
Trial: 39112795
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment
Trial: 34042953
Drug: Biological VNN
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological VNN (BioVNN)
Trial: 34159208
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PRP treatment)
Trial: 32801102
Drug: Adjunctive eslicarbazepine
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive eslicarbazepine acetate (ESL) 1200 mg once daily (QD)
Trial: 32801102
Drug: Adjunctive eslicarbazepine
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive eslicarbazepine acetate (ESL) 800 mg once daily (QD)
Trial: 33864234
Drug: Continued Behavioral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued Behavioral Weight-Loss Treatment (Control)
Trial: 33864234
Drug: Post-Treatment Weight-Related
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-Treatment Weight-Related Experiential Avoidance (AAQW-R)
Trial: 34878953
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 440 mg (NapS)
Trial: 34878953
Drug: Hydrocodone plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone plus acetaminophen 10/650 mg (HYD+APAP)
Trial: 36058564
Drug: Methylprednisolone taper
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone taper (MPT) course following surgery
Trial: 32829027
Drug: Aflibercept monotherapy
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept monotherapy (control group)
Trial: 35346048
Drug: Intraoperative dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative dopamine infusion
Trial: 32436160
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate lozenges
Trial: 32436160
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate tablets
Trial: 32436160
Drug: Placebo (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets or lozenges)
Trial: 35887695
Drug: Andrographis paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata (AP) 1000 mg
Trial: 35887695
Drug: Andrographis paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata (AP) 2000 mg
Trial: 33526618
Drug: Filgotinib monotherapy
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filgotinib monotherapy
Trial: 34124817
Drug: Salivary IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary IgA antibodies to MAA‐LDL
Trial: 34124817
Drug: Salivary IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary IgA antibodies to heat shock protein 60 of Aggregatibacter actinomycetemcomitans
Trial: 34124817
Drug: Salivary IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary IgA antibodies to Porphyromonas gingivalis
Trial: 34124817
Drug: Salivary IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary IgA antibodies to A. actinomycetemcomitans
Trial: 34124817
Drug: Salivary IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salivary IgA antibodies to P. intermedia
Trial: 34936830
Drug: Cyproheptadine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (8 mg)
Trial: 36256912
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg once daily plus olaparib 200 mg twice daily
Trial: 36256912
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg twice daily alone
Trial: 36256912
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg once daily plus olaparib 200 mg twice daily in HRR-deficient mCRPC
Trial: 36256912
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg twice daily alone in HRR-deficient mCRPC
Trial: 36256912
Drug: Cediranib 30
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 30 mg once daily plus olaparib 200 mg twice daily in BRCA2-mutated mCRPC
Trial: 36256912
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg twice daily alone in BRCA2-mutated mCRPC
Trial: 33001491
Drug: TMFI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMFI + ALA-cream
Trial: 33001491
Drug: TMFI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMFI + ALA-gel
Trial: 33001491
Drug: ALA-cream
RxNorm normalized name: hydrocortisone Topical Cream [Ala-Cort]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-cream
Trial: 33676327
Drug: Nomogram with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram with independent risk factors (older age ≥65 years, female gender, hemorrhagic stroke, malignancy, lower limb muscle strength <3 grade, Albumin <40 g·L−1, D‐dimer >0.5 mg·L−1)
Trial: 33843663
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OT) group, 20-25 μg/ml ozone concentration, 30 ml, 8 sessions total
Trial: 33843663
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (PC) group, 0.1 μg/ml ozone concentration, 30 ml, 8 sessions total
Trial: 32127336
Drug: Low-dose prasugrel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prasugrel (5 mg)
Trial: 35776501
Drug: GAD-alum (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (4 μg) administered intralymphatically three times with 1 month interval
Trial: 35869467
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (Control group)
Trial: 32856619
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of a carbohydrate beverage
Trial: 32446951
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone before radiation therapy followed by 3 daily doses (group A)
Trial: 32446951
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone followed by 3 doses of placebo (group B)
Trial: 32446951
Drug: 4 doses
RxNorm normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of placebo (group C)
Trial: 33547676
Drug: CGRP monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP monoclonal antibody
Trial: 35033011
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of PPI (Group A)
Trial: 35033011
Drug: Gradual tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual tapering of PPI (Group B)
Trial: 33856549
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus topical ketorolac
Trial: 33501601
Drug: HCB (HCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCB (HCD supplemented with 50 mg/kg berberine)
Trial: 34435584
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg, 300 mg, 600 mg (single doses)
Trial: 32694286
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation oral contraceptives (OC)
Trial: 32694286
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of oral contraceptives (non-OC)
Trial: 36424580
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg subcutaneously daily for a mean of 18 months (range 14–24 months)
Trial: 32024027
Drug: Sucrosomial ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrosomial ferric pyrophosphate plus L‐ascorbic acid (30-day oral therapy)
Trial: 32327497
Drug: PEGasparaginase individualized
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEGasparaginase individualized dosing based on therapeutic drug monitoring
Trial: 32327497
Drug: PEGasparaginase during
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEGasparaginase during induction treatment
Trial: 32327497
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of PEGasparaginase
Trial: 32070417
Drug: Web-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based treatment program with therapist guidance
Trial: 39082471
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (ARB)
Trial: 35789991
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (60,000 IU monthly for 5 years)
Trial: 33785488
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (unsupervised exercises and referral for physiotherapy or exercise therapy upon request)
Trial: 35710440
Drug: Clindamycin capsules
RxNorm normalized name: clindamycin Oral Capsule
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin capsules for 10 days
Trial: 35241469
Drug: Palbociclib in
RxNorm normalized name: Product containing palbociclib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib in combination with an aromatase inhibitor (AI)
Trial: 35241469
Drug: Palbociclib in
RxNorm normalized name: Product containing palbociclib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib in combination with fulvestrant
Trial: 32589632
Drug: Household Treatment
RxNorm normalized name: ALLERGENIC EXTRACT INSECTS HOUSEHOLD INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household Treatment group (all family members treated)
Trial: 32589632
Drug: Individual Treatment
RxNorm normalized name: Alex Rubber Tip Individual Pack 3/4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Treatment group (only affected participants treated)
Trial: 32589632
Drug: Household Treatment
RxNorm normalized name: ALLERGENIC EXTRACT INSECTS HOUSEHOLD INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household Treatment group
Trial: 32589632
Drug: Individual Treatment
RxNorm normalized name: Alex Rubber Tip Individual Pack 3/4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Treatment group
Trial: 36038262
Drug: Treg infusions
RxNorm normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treg infusions (1 × 10^6 cells/kg) IV every 4 weeks and IL-2 (2 × 10^5 IU/m2) injections 3 times/week
Trial: 36038262
Drug: Treg infusions
RxNorm normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treg infusions (2 × 10^6 cells/kg and 3 × 10^6 cells/kg) in OLE
Trial: 36038262
Drug: Treg/IL-2 treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treg/IL-2 treatments
Trial: 33818395
Drug: Treatment app
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment app (including pelvic floor muscle training, bladder training, psychoeducation, lifestyle advice, tailored advice, exercise log, reinforcement messages, and reminders)
Trial: 33818395
Drug: Treatment app
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment app
Trial: 36476386
Drug: Online behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online behavior change intervention with weekly individual online sessions for 12 weeks and an activity monitor
Trial: 36476386
Drug: Weekly individual
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly individual online sessions for 12 weeks
Trial: 34117190
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention addressing living with a PCN tube, provided twice (before placement and at first tube change, 6 weeks later)
Trial: 39663175
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT)
Trial: 35022779
Drug: COVID-19-directed therapies
RxNorm normalized name: DIRECT BLACK 19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19-directed therapies
Trial: 38507688
Drug: Systemic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids
Trial: 35724261
Drug: Amoxicillin-Potassium Clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-Potassium Clavulanate
Trial: 34470831
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (100 mg biweekly, total 2 grams)
Trial: 34470831
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (500 mg every 10 weeks, total 2 grams)
Trial: 34470831
Drug: Erythropoiesis stimulating
RxNorm normalized name: Erythropoiesis stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis stimulating agent dosing
Trial: 35555966
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of triamcinolone acetonide
Trial: 35555966
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser therapy followed by topical application of the drug for six sessions
Trial: 33059771
Drug: Adsorbed COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac, 3 μg/0.5 mL (600 SU per dose), two doses IM with a two-week interval.
Trial: 33059771
Drug: Placebo containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo containing aluminium hydroxide in a 0.5 mL solution, two doses IM with a two-week interval.
Trial: 32909643
Drug: apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apremilast 30 mg b.i.d.
Trial: 35304977
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 200 mg cyclosporine
Trial: 35304977
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 600 mg quinidine
Trial: 33687763
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (etoposide and carboplatin or cisplatin)